SRTS (Sensus Healthcare) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRTS Sensus Healthcare Inc SRTS
75 GF Score
Price $3.14
GF Value $2.71
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sensus Healthcare Short-term investments?

Short-term investments only applies to insurance companies.

SRTS
75GF Score
Sensus Healthcare Inc SRTS
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sensus Healthcare (SRTS) Overvalued in 2026?

Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued. The current stock price of $3.14 is trading 15.9% above its estimated GF Value™ of $2.71. GuruFocus considers Sensus Healthcare to be Modestly Overvalued.

Key valuation signals for SRTS:

  • Short-term investments:
  • GF Value™: $2.71 vs. price of $3.14 (15.9% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sensus Healthcare Business Description

Other Exchanges 5TX:Germany
Address 851 Broken Sound Parkway, NW, Suite 215, Boca Raton, FL, USA, 33487
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
75GF Score

Get the complete analysis for SRTS

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.14
Price
$2.71
GF Value